RxDoctor Payments Data

Mamta Kanwar, MD

Ophthalmology · Livonia, MINPI 1346738002

Payments from drug & device makers

$2,876in general payments, 2019–2025

Across 37 payments — averaging $77.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Sight Sciences, Inc.$218
  • Glaukos Corporation$195
  • AbbVie$178
  • Regeneron Healthcare Solutions, Inc.$124
  • Dompe US, Inc.$72
  • plus $157 from 5 others

What the payments were for

  • Travel & lodging$1,12539%
  • Food & beverage$1,75061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,876 in reported general payments places this provider in the 70th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$175,117
Medicare patients
407
Services billed
1,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost73$37,893
RestasisCyclosporine18$24,903
LumiganBimatoprost31$14,867
Latanoprost660$13,292
RhopressaNetarsudil Mesylate35$12,908
CombiganBrimonidine Tartrate/Timolol21$12,815
VyzultaLatanoprostene Bunod35$12,042
Cyclosporine16$10,949
Prednisolone Acetate196$9,737
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$9,291
Timolol Maleate288$7,918
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat260$7,621
SimbrinzaBrinzolamide/Brimonidine Tart25$7,118
Brimonidine Tartrate261$4,992
Dorzolamide Hcl134$3,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$178$52,58470 claims
Bausch & Lomb Americas Inc.Vyzulta$52$12,04235 claims
AlconSimbrinza$1,932$7,11825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →